Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
13
6
2019
medline:
25
5
2021
entrez:
13
6
2019
Statut:
ppublish
Résumé
To evaluate the potential changes in the plasma levels of resolvin D1 (RvD1) in patients with trauma and hemorrhage. Having found that trauma results in a profound reduction in plasma RvD1 in patients, we have then investigated the effects of RvD1 on the organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat. HS is a common cause of death in trauma due to excessive systemic inflammation and multiple organ failure. RvD1 is a member of the resolvin family of pro-resolution mediators. Blood samples were drawn from critically injured patients (n = 27, ACITII-prospective observational cohort study) within 2 hours of injury for targeted liquid chromatography tandem mass spectrometry. HS rats (removal of blood to reduce arterial pressure to 30 ± 2 mm Hg, 90 minutes, followed by resuscitation) were treated with RvD1 (0.3 or 1 μg/kg intravenous (i.v.)) or vehicle (n = 7). Parameters of organ injury and dysfunction were determined. Plasma levels of RvD1 (mg/dL) were reduced in patients with trauma+HS (0.17 ± 0.08) when compared with healthy volunteers (0.76 ± 0.25) and trauma patients (0.62 ± 0.20). In rats with HS, RvD1 attenuated the kidney dysfunction, liver injury, and tissue ischemia. RvD1 also reduced activation of the nuclear factor (NF)-κB pathway and reduced the expression of pro-inflammatory proteins such as inducible nitric oxide synthase, tumor necrosis factor-α, interleukin-1β, and interleukin-6. Plasma RvD1 is reduced in patients with trauma-HS. In rats with HS, administration of synthetic RvD1 on resuscitation attenuated the multiple organ failure associated with HS by a mechanism that involves inhibition of the activation of NF-κB.
Sections du résumé
OBJECTIVE
To evaluate the potential changes in the plasma levels of resolvin D1 (RvD1) in patients with trauma and hemorrhage. Having found that trauma results in a profound reduction in plasma RvD1 in patients, we have then investigated the effects of RvD1 on the organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat.
BACKGROUND
HS is a common cause of death in trauma due to excessive systemic inflammation and multiple organ failure. RvD1 is a member of the resolvin family of pro-resolution mediators.
METHODS
Blood samples were drawn from critically injured patients (n = 27, ACITII-prospective observational cohort study) within 2 hours of injury for targeted liquid chromatography tandem mass spectrometry. HS rats (removal of blood to reduce arterial pressure to 30 ± 2 mm Hg, 90 minutes, followed by resuscitation) were treated with RvD1 (0.3 or 1 μg/kg intravenous (i.v.)) or vehicle (n = 7). Parameters of organ injury and dysfunction were determined.
RESULTS
Plasma levels of RvD1 (mg/dL) were reduced in patients with trauma+HS (0.17 ± 0.08) when compared with healthy volunteers (0.76 ± 0.25) and trauma patients (0.62 ± 0.20). In rats with HS, RvD1 attenuated the kidney dysfunction, liver injury, and tissue ischemia. RvD1 also reduced activation of the nuclear factor (NF)-κB pathway and reduced the expression of pro-inflammatory proteins such as inducible nitric oxide synthase, tumor necrosis factor-α, interleukin-1β, and interleukin-6.
CONCLUSION
Plasma RvD1 is reduced in patients with trauma-HS. In rats with HS, administration of synthetic RvD1 on resuscitation attenuated the multiple organ failure associated with HS by a mechanism that involves inhibition of the activation of NF-κB.
Identifiants
pubmed: 31188196
pii: 00000658-202105000-00026
doi: 10.1097/SLA.0000000000003407
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
resolvin D1
0
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1012-1021Informations de copyright
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest.
Références
Dimaggio C, Ayoung-Chee P, Shinseki M, et al. Traumatic injury in the United States: in-patient epidemiology 2000–2011. Injury 2016; 47:1393–1403.
Krug EG, Sharma GK, Lozano R. The global burden of injuries. Am J Public Health 2000; 90:523–526.
Mira JC, Cuschieri J, Ozrazgat-Baslanti T, et al. The epidemiology of chronic critical illness after severe traumatic injury at two-level one trauma centers. Crit Care Med 2017; 45:1989–1996.
Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med 2011; 17:1391–1401.
Jarrar D, Chaudry IH, Wang P. Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches. Int J Mol Med 1999; 4:575–583.
Thiemermann C, Szabó C, Mitchell J, et al. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A 1993; 90:267–271.
Huber-Lang M, Lambris JD, Ward PA. Innate immune responses to trauma. Nat Immunol 2018; 19:327–341.
Sordi R, Nandra KK, Chiazza F, et al. Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation. Ann Surg 2017; 265:408–417.
Sordi R, Chiazza F, Johnson FL, et al. Inhibition of IkB kinase attenuates the organ injury and dysfunction associated with hemorrhagic shock. Mol Med 2015; 21:563–575.
Sordi R, Chiazza F, Collino M, et al. Neuronal nitric oxide synthase is involved in vascular hyporeactivity and multiple organ dysfunction associated with hemorrhagic shock. Shock 2016; 45:525–533.
Yamada N, Martin LB, Zechendorf E, et al. Novel synthetic, host-defense peptide protects against organ injury/dysfunction in a rat model of severe hemorrhagic shock. Ann Surg 2018; 268:348–356.
Gilroy DW, Lawrence T, Perretti M, et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3:401–416.
Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008; 3:279–312.
Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8:349–361.
Norling LV, Headland SE, Dalli J, et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight 2016; 1:e85922.
Xu ZZ, Ji RR. Resolvins are potent analgesics for arthritic pain. Br J Pharmacol 2011; 164:274–277.
Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461:1287–1291.
Sordi R, Menezes-de-Lima O Jr, Horewicz OM, et al. Dual role of lipoxin A 4 in pneumosepsis pathogenesis. Int Immunopharmacol 2013; 17:283–292.
Inoue Y, Yu Y, Kurihara T, et al. Kidney and liver injuries after major burns in rats are prevented by Resolvin D2 2016; 44:e241–e252.
Settimio R, Clara DF, Franca F, et al. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis. Mediators Inflamm 2012; 2012:318621.
Menezes-de-Lima O, Kassuya CAL, Nascimento AFZ, et al. Lipoxin A4 inhibits acute edema in mice: implications for the anti-edematogenic mechanism induced by aspirin. Prostaglandins Other Lipid Mediat 2006; 80:123–135.
Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21:325–332.
Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6:1191–1197.
Liao Z, Dong J, Wu W, et al. Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPAR (/NF-(B pathway. Respir Res 2012; 13:110.
Dmitrieva N, Suess G, Shirley R. Resolvins RvD1 and 17 (R)-RvD1 alleviate signs of inflammation in a rat model of endometriosis. Fertil Steril 2014; 102:1191–1196.
Chen F, Fan XH, Wu YP, et al. Resolvin D1 improves survival in experimental sepsis through reducing bacterial load and preventing excessive activation of inflammatory response. Eur J Clin Microbiol Infect Dis 2014; 33:457–464.
Cohen MJ, Carles M, Brohi K, et al. Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans. J Trauma 2010; 68:1273–1278.
Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 2011; 255:379–385.
Ciesla DJ, Moore EE, Johnson JL, et al. Multiple organ dysfunction during resuscitation is not postinjury multiple organ failure. Arch Surg 2004; 139:590–595.
Cabrera CP, Manson J, Shepherd JM, et al. Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: a prospective cohort study. PLoS Med 2017; 14:e1002352.
Antonelli M, Moreno R, Vincent JL, et al. Application of SOFA score to trauma patients. Intensive Care Med 1999; 25:389–394.
Dalli J, Colas RA, Serhan CN. Novel n-3 immunoresolvents: structures and actions. Sci Rep 2013; 3:1940.
Rathod KS, Kapil V, Velmurugan S, et al. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest 2017; 127:169–182.
Sordi R, Chiazza F, Patel NSA, et al. Preconditioning” with low dose lipopolysaccharide aggravates the organ injury/dysfunction caused by hemorrhagic shock in rats. PLoS One 2015; 10:e0122096.
Motwani MP, Colas RA, George MJ, et al. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation. JCI Insight 2018; 3:pii: 94463.
Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196:1025–1037.
Zhao YL, Zhang L, Yang YY, et al. Resolvin D1 protects lipopolysaccharide-induced acute kidney injury by down-regulating nuclear factor-kappa B signal and inhibiting apoptosis. Chin Med J (Engl) 2016; 129:1100–1107.
Lima-Garcia JF, Dutra RC, Da Silva KABS, et al. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol 2011; 164:278–293.
Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010; 107:1660–1665.
Norling LV, Dalli J, Flower RJ, et al. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol 2012; 32:1970–1978.
Ramon S, Bancos S, Serhan CN, et al. Lipoxin A4 modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism. Eur J Immunol 2014; 44:357–369.
Chattopadhyay R, Mani AM, Singh NK, et al. Resolvin D1 blocks H2O2-mediated inhibitory crosstalk between SHP2 and PP2A and suppresses endothelial-monocyte interactions. Free Radic Biol Med 2018; 117:119–131.
Hsiao H-M, Thatcher TH, Levy EP, et al. Resolvin D1 attenuates polyinosinic-polycytidylic acid–induced inflammatory signaling in human airway epithelial cells via TAK1. J Immunol 2014; 193:4980–4987.
Zhang Y, Zhang J, Korff S, et al. Delayed neutralization of interleukin 6 reduces organ injury, selectively suppresses inflammatory mediator, and partially normalizes immune dysfunction following trauma and hemorrhagic shock. Shock 2014; 42:218–227.
Sauaia A, Moore FA, Moore EE. Postinjury inflammation and organ dysfunction. Crit Care Clin 2017; 33:167–191.
Meng ZH, Dyer K, Billiar TR, et al. Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock. Am J Physiol Cell Physiol 2001; 280:C343–C351.
Adib-Conquy M, Moine P, Asehnoune K, et al. Toll-like receptor-mediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med 2003; 168:158–164.
Roquilly A, Broquet A, Jacqueline C, et al. Hydrocortisone prevents immunosuppression by interleukin-10+ natural killer cells after trauma-hemorrhage. Crit Care Med 2014; 42:e752–e761.
Murakami T, Suzuki K, Tamura H, et al. Suppressive action of resolvin D1 on the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice. Exp Ther Med 2011; 2:57–61.
Shinohara M, Kibi M, Riley IR, et al. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. AJP Lung Cell Mol Physiol 2014; 307:L746–L757.